Roche Reports Strong 2023 Financial Results with 324% Surge in Ophthalmology Bispecific Antibody Vabysmo

Roche's business mainly consists of two parts: pharmaceuticals and diagnostics.

• From the perspective of the business department

Pharmaceuticals Division Sales Reach 44.6 Billion Swiss Francs, Increased by 6% year-on-year，This is thanks toTop Five Growth Drivers—Vabysmo (severe eye diseases), Ocrevus (multiple sclerosis), Hemlibra (hemophilia A), Polivy (blood cancer), and Phesgo (breast cancer) collectively achieved total sales of 14.8 billion Swiss francs.Compared to 2022, calculated at CER,These products combinedContributed an additional 4.3 billion Swiss francs in sales.

Ophthalmic DrugsVabysmo remains the largest growth driver (+324%)。Vabysmo, launched in early 2022, has achieved sales of 2.4 billion Swiss francs and has become one of Roche's best-selling drugs.

Vabysmo has now been approved in the EU and nine other countries worldwide (including the United States, Japan, and the United Kingdom) for patients with "wet" age-related macular degeneration and diabetic macular edema.

Diagnostic division sales were CHF 14.1 billion, a decrease of 13%.At constant exchange rates), due to a decline in sales related to COVID-19 testing.

• Pharmaceuticals Division - Sales by Region

• Pharmaceutical Research and Development (R&D)

• Outlook for 2024

Looking Forward to 202In 4 years, Roche expects group sales to achieve mid-single-digit growth.The target for core earnings per share is to grow in line with sales (at constant exchange rates), excluding the impact of resolving tax disputes in 2023. Roche expects to further increase the dividend denominated in Swiss francs.

Roche CEO Thomas Schinecker stated"We achieved good sales growth, offsetting the sharp decline in COVID-19 sales.Roche's core business (excluding COVID-19) continues to maintain strong growth momentum, with a +8% increase at constant exchange rates.。Therefore, we exceeded the guidance for 2023. Meanwhile,The significant appreciation of the Swiss franc against most currencies has severely impacted performance denominated in Swiss francs.. We have also made good progress in our pharmaceuticals and diagnostics pipeline.A recent highlight is inavolisib, an oral therapy being studied in a Phase III trial., the therapy shows, reducing the risk of death or disease progression by more than 50% in patients with advanced, difficult-to-treat breast cancer.We look forward to bringing this drug to patients as soon as possible. Our new partnerships and acquisitions address disease areas with highly unmet needs, such as inflammatory bowel disease and cardiometabolic disorders. We are well-prepared for future growth.